Latest Strategy News

Celsius Resources has delivered a robust Definitive Feasibility Study for its Maalinao-Caigutan-Biyog Copper-Gold Project, confirming a 35-year mine life and strong economic returns. The company is actively progressing funding arrangements amid growing investor interest.

Nimy Resources has announced a maiden JORC Inferred Resource for high-grade gallium and rare earth elements at its Mons Project in Western Australia, marking a significant step towards becoming a key supplier in critical minerals.

Vita Resources NL, formerly Bastion Minerals, has advanced its Canadian and Australian projects with new exploration agreements and acquisitions, supported by a recent capital raise. The company is gearing up for significant exploration activities in 2026 under its refreshed corporate identity.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

Cullen Resources Limited has outlined an active exploration agenda for early 2026, advancing drilling programs across its gold and base metal projects in Western Australia and Finland while maintaining a stable financial footing.

Manuka Resources has released an updated 10-year Pre-Feasibility Study for its Cobar Basin projects, revealing a substantial uplift in project economics and a clear path to production by mid-2026.

Emerald Resources NL reported solid December quarter gold production from its Okvau Gold Mine and significant resource upgrades at its Dingo Range and Memot projects, underpinning its growth trajectory.

Magmatic Resources has reported encouraging gold assay results from its Weebo Gold Project and advanced drilling at its Myall Copper-Gold JV, alongside securing a $3 million placement led by FMG Resources.

MRG Metals has expanded its rare earth portfolio through the acquisition of the high-grade Garies Rare Earth Project in South Africa, while also progressing key projects in Mozambique, signalling a diversified growth strategy in critical minerals.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Evion Group gains momentum as the US-Africa Strategic Infrastructure and Investment Working Group fosters trade, Madagascar accelerates mining permits, and Indian graphite operations deliver strong sales.

PainChek has secured FDA De Novo clearance, enabling entry into the vast US healthcare market with a $3 billion Remote Therapeutic Monitoring opportunity. The company reports $5.6 million contracted ARR and a strong global footprint in aged care.